COMP <GO>
CRIS vs PMCB // EV/EBITDA & P/E VALUATION
Curis Inc. (NASDAQ) VS. PharmaCyte Biotech Inc. (NASDAQ) • 15-METRIC TALLY: CRIS 2
— PMCB 2
■ METRIC PARITY
LAST: $0.55 (+20.82%) • MKT CAP: $3.7M
valuation
—
LAST: $0.33 (-0.78%) • MKT CAP: $3.6M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRIS VS. PMCB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRIS | PMCB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -30.20% | -4.80 | PMCB | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -13.40% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 2/9 | -1.00 | PMCB | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.2 | 25.9 | +16.25 | CRIS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.7M | $3.6M | $98.2K | CRIS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRIS REV | PMCB REV | CRIS GROSS % | PMCB GROSS % | CRIS FCF | PMCB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $9.4M | $0 | — | — | -$27.2M | -$5.2M |
| FY 2024 | $10.9M | $0 | — | — | -$39.6M | -$3.0M |
| FY 2023 | $10.0M | $0 | — | — | -$38.4M | -$2.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRIS // BETA —
PMCB // BETA —